Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Other Gross PP&E Adjustments (2019 - 2025)

Myriad Genetics (MYGN) has disclosed Other Gross PP&E Adjustments for 12 consecutive years, with $146.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments fell 11.19% to $146.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $146.9 million, a 11.19% decrease, with the full-year FY2025 number at $146.9 million, down 11.19% from a year prior.
  • Other Gross PP&E Adjustments was $146.9 million for Q4 2025 at Myriad Genetics, up from $144.1 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $233.0 million in Q3 2023 to a low of $59.5 million in Q2 2021.
  • A 5-year average of $134.0 million and a median of $144.1 million in 2025 define the central range for Other Gross PP&E Adjustments.
  • Peak YoY movement for Other Gross PP&E Adjustments: skyrocketed 390.12% in 2021, then dropped 24.76% in 2024.
  • Myriad Genetics' Other Gross PP&E Adjustments stood at $64.1 million in 2021, then surged by 32.76% to $85.1 million in 2022, then skyrocketed by 102.47% to $172.3 million in 2023, then fell by 4.0% to $165.4 million in 2024, then dropped by 11.19% to $146.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Other Gross PP&E Adjustments are $146.9 million (Q4 2025), $144.1 million (Q3 2025), and $141.2 million (Q2 2025).